Adc Therapeutics SA Forecast, price target & analysts
Adc Therapeutics SA Target price 2025 - Analyst rating & recommendation
Adc Therapeutics SA Classifications & Recommendation:
Adc Therapeutics SA Price Target
| Target Price | $8.20 |
| Price | $3.51 |
| Potential |
133.62%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Adc Therapeutics SA 2026 .
The average Adc Therapeutics SA target price is $8.20.
This is
133.62%
register free of charge
$10.00
184.90%
register free of charge
$7.00
99.43%
register free of charge
|
|
| A rating was issued by 6 analysts: 6 Analysts recommend Adc Therapeutics SA to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adc Therapeutics SA stock has an average upside potential 2026 of
133.62%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 70.84 | 77.50 |
| 1.84% | 9.40% | |
| Net Margin | -222.83% | -204.34% |
| 35.43% | 8.30% |
6 Analysts have issued a sales forecast Adc Therapeutics SA 2025 . The average Adc Therapeutics SA sales estimate is
This results in the following potential growth metrics:
6 Adc Therapeutics SA Analysts have issued a net profit forecast 2025. The average Adc Therapeutics SA net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.62 | -1.60 |
| 44.90% | 1.23% | |
| P/E | negative | |
| EV/Sales | 7.67 |
6 Analysts have issued a Adc Therapeutics SA forecast for earnings per share. The average Adc Therapeutics SA EPS is
This results in the following potential growth metrics and future valuations:
Adc Therapeutics SA...
Current Adc Therapeutics SA Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | May 15 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 06 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Dec 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Feb 24 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 06 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Dec 12 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
